Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1319

Sort by

Sort Order Select

Journal Articles

RUNX-1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells

Brian Estevez, Sara Borst, Danuta Jarocha, Varun Sudunagunta, Michael Gonzalez, James Garifallou, Hakon Hakonarson, Peng Gao, Kai Tan, Paul Liu, Sumedha Bagga, Nicholas Holdreith, Wei Tong, Nancy Speck, Deborah L. French, Paul Gadue, Mortimer Poncz

Blood (2021) 137 (19): 2662–2675.

https://doi.org/10.1182/blood.2020006389

Published: 2021

Includes: Supplemental data

Journal Articles

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Erica B. Esrick, MD, Maureen Achebe, MD MPH, Myriam Armant, PhD, Pablo Bartolucci, MD PhD, Marioara Felicia Ciuculescu, MD, Heather Daley, Colleen Dansereau, MSN, RN, CPN, Giuseppe Di Caprio, PhD, Bronner Goncalves, MD PhD, Nicolas Hebert, Matthew M Heeney, MD, John M. Higgins, MD PhD, Leslie E. Lehmann, MD, John P Manis, MD, Olivier Negre, PhD, Sarah Nikiforow, MD PhD, Ethan Schonbrun, PhD, David K. Wood, PhD, David A. Williams, MD

Blood (2019) 134 (Supplement_2): LBA-5.

https://doi.org/10.1182/blood-2019-132745

Published: 2019

Journal Articles

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Eric Lowe, BS, Andrea R Fan, PhD, Jing Jiang, Henry W. B. Johnson, PhD, Christopher J. Kirk, PhD, Dustin McMinn, PhD, Tony Muchamuel, MS, Yu Qian, PhD, Brian B. Tuch, PhD

Blood (2019) 134 (Supplement_1): 408.

https://doi.org/10.1182/blood-2019-123782

Published: 2019

Journal Articles

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

Blood (2019) 134 (Supplement_1): 474.

https://doi.org/10.1182/blood-2019-127235

Published: 2019

Journal Articles

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Bhavuk Garg, PhD, Hrishikesh M Mehta, PhD, Ralph Kamel, Marshall S. Horwitz, MD PhD, Seth J. Corey, MD

Blood (2019) 134 (Supplement_1): 103.

https://doi.org/10.1182/blood-2019-127409

Published: 2019

Journal Articles

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

Johannes M. Waldschmidt, MD, Jake A. Kloeber, Tushara Vijaykumar, Antonis Kokkalis, PhD MSc, Praveen Anand, PhD, Sayalee Potdar, Julia Frede, PhD MPhil, Monica S. Nair, Valeriya Dimitrova, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Andrew J. Yee, MD, Noopur S. Raje, MD, Birgit Knoechel, MD PhD, Jens G. Lohr, MD PhD

Blood (2019) 134 (Supplement_1): 316.

https://doi.org/10.1182/blood-2019-130313

Published: 2019

Journal Articles

The Inherited Platelet Disorder of RUNX1 Haploinsufficiency (Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)) Has a Marked Deficiency of Megakaryocyte-Biased Hematopoietic Progenitor Cells: Mechanistic Studies and Drug Correction

Brian Estevez, PhD, Sara Borst, BS, Danuta Jadwiga Jarocha, PhD, Varun Sudunagunta, Michael Gonzalez, PhD, Peng Gao, Kai Tan, Deborah L French, PhD, Paul Gadue, PhD, Mortimer Poncz, MD

Blood (2019) 134 (Supplement_1): 220.

https://doi.org/10.1182/blood-2019-124851

Published: 2019

Journal Articles

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Yuyin Li, PhD, Liang Lin, PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Tengteng Yu, MD PhD, Gang An, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4381.

https://doi.org/10.1182/blood-2019-130297

Published: 2019

Journal Articles

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Brian A Walker, PhD, Frits van Rhee, MD PhD

Blood (2019) 134 (Supplement_1): 4383.

https://doi.org/10.1182/blood-2019-130493

Published: 2019

Journal Articles

Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma

Staci L. Haney, PhD, Michelle L. Varney, MS, Lynette M. Smith, PhD, Sarah A. Holstein, MD PhD

Blood (2019) 134 (Supplement_1): 4417.

https://doi.org/10.1182/blood-2019-129244

Published: 2019

Journal Articles

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Andrea Ghelli Luserna Di Rorà, PhD, Antonella Padella, PhD, Maria Chiara Fontana, PhD, Eugenio Fonzi, PhD, Anna Ferrari, PhD, Enrica Imbrogno, PhD, Martina Ghetti, PhD, Roberta Napolitano, PhD, Maria Teresa Bochicchio, Giovanni Martinelli, MD, Giorgia Simonetti, PhD

Blood (2019) 134 (Supplement_1): 5047.

https://doi.org/10.1182/blood-2019-129964

Published: 2019

Journal Articles

Downregulation of MDM2 Leads to Anti-Proliferative Effects through Activation of p53-Associated Pathway Mediated By Both Dual Inhibitor MX69 and Mir-548c-3p in Multiple Myeloma

Faruq Faruq, PhD, Davidson Zhao, Jian Wu, MD, Jonahunnatha Nesson George William, PhD, Min Zhang, MD, Hong Chang, MD

Blood (2019) 134 (Supplement_1): 4419.

https://doi.org/10.1182/blood-2019-129430

Published: 2019

Journal Articles

Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia

Henning D. Popp, Vanessa Kohl, MSc, Johanna Flach, PhD, Susanne Brendel, MTA, Helga Kleiner, MTA, Wolfgang Seifarth, PhD, Christel Weiss, PhD, Susanne Saussele, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD

Blood (2019) 134 (Supplement_1): 5364.

https://doi.org/10.1182/blood-2019-122698

Published: 2019

Journal Articles

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Andrea Tomirotti, PhD, Giuseppe Merlino, Alessio Fiascarelli, PhD, Simone Baldini, MD, Alessia Tagliavini, Elisa Borella, Milena Mazan, PhD, Krzysztof Brzózka, PhD, Alessandro Bressan, Andrea Pellacani, PhD MD, Massimiliano Salerno, Monica Binaschi, PhD, Daniela Bellarosa

Blood (2019) 134 (Supplement_1): 5087.

https://doi.org/10.1182/blood-2019-124800

Published: 2019

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

Inhibition of Acute Leukemia By a Small Molecule KYA1797K Which Destabilize RAS and β-Catenin

Seungmin Hahn, MD, Mi Ra Lee, Jungwoo Han, MD PhD, Moon Kyu Kim, Seung-Hwan Oh, Chuhl Joo Lyu, MD PhD

Blood (2019) 134 (Supplement_1): 5758.

https://doi.org/10.1182/blood-2019-126374

Published: 2019

Journal Articles

Microbial-Derived Metabolites Drive Protective Type-I Interferon Responses in Models of Gut Epithelial Damage and Limit Graft-Versus-Host Disease

Erik Thiele Orberg, MD PhD, Sascha Göttert, Hendrik Poeck, MD

Blood (2019) 134 (Supplement_1): 3207.

https://doi.org/10.1182/blood-2019-125850

Published: 2019

Journal Articles

SETBP1 Mutations Accelerate NRAS-Mutant Leukemia

Sarah A Carratt, PhD BS, Zachary Schonrock, BS, Theodore Braun, MD PhD, Cody Coblentz, Amy Foley, MEng., Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 1254.

https://doi.org/10.1182/blood-2019-125125

Published: 2019

Journal Articles

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Nakhle S. Saba, MD, Jade Meyers, Lorena Fontan, PhD, Ari Melnick, MD, Adrian Wiestner, MD PhD, Patricia Lobelle-Rich, Ekaterina Kim, MS, Jan A. Burger, MD PhD, Yara Mouawad, MD, Prescott L. Deininger, PhD, Francisco Socola, MD, Hana Safah, MD, Erik K Flemington, PhD

Blood (2019) 134 (Supplement_1): 1288.

https://doi.org/10.1182/blood-2019-131376

Published: 2019

Journal Articles

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Sunil K Joshi, BA, William Bisson, PhD, Kristin Qian, Ariane Huang, Kevin Watanabe-Smith, PhD, Jeffrey W. Tyner, Monika Ashok Davare, PhD, Shannon K. McWeeney, PhD, Cristina E. Tognon, Brian J. Druker

Blood (2019) 134 (Supplement_1): 1256.

https://doi.org/10.1182/blood-2019-125908

Published: 2019

NARROW

RUNX-1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

The Inherited Platelet Disorder of RUNX1 Haploinsufficiency (Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)) Has a Marked Deficiency of Megakaryocyte-Biased Hematopoietic Progenitor Cells: Mechanistic Studies and Drug Correction

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Downregulation of MDM2 Leads to Anti-Proliferative Effects through Activation of p53-Associated Pathway Mediated By Both Dual Inhibitor MX69 and Mir-548c-3p in Multiple Myeloma

Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Inhibition of Acute Leukemia By a Small Molecule KYA1797K Which Destabilize RAS and β-Catenin

Microbial-Derived Metabolites Drive Protective Type-I Interferon Responses in Models of Gut Epithelial Damage and Limit Graft-Versus-Host Disease

SETBP1 Mutations Accelerate NRAS-Mutant Leukemia

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only